24-Hydroxycholesterol participates in pancreatic neuroendocrine tumor development

Matías Soncini(IRCCS Ospedale San Raffaele), Gianfranca Corna(IRCCS Ospedale San Raffaele), Marta Angiola Moresco(IRCCS Ospedale San Raffaele), Nadia Coltella(Vita-Salute San Raffaele University), Umberto Restuccia(IFOM), Daniela Maggioni(IRCCS Ospedale San Raffaele), Laura Raccosta(IRCCS Ospedale San Raffaele), Chin‐Yo Lin(University of Houston), Francesca Invernizzi(San Raffaele University of Rome), Roberto Crocchiolo(MolMed (Italy)), Claudio Doglioni(Vita-Salute San Raffaele University), Catia Traversari(MolMed (Italy)), Angela Bachi(IFOM), Rosa Bernardi(Vita-Salute San Raffaele University), Claudio Bordignon(Vita-Salute San Raffaele University), Jan-Ακε Gustafsson(University of Houston), Vincenzo Russo(IRCCS Ospedale San Raffaele)
Proceedings of the National Academy of Sciences
September 26, 2016
Cited by 68Open Access
Full Text

Abstract

Significance Oxysterols promote tumor growth directly or through the dampening of tumor-infiltrating immune cells. Whether oxysterols contribute to pancreatic neuroendocrine tumor (pNET) development and how they are generated within the pNET microenvironment are currently unknown. Here, we show that the 24S-hydroxycholesterol (24S-HC) oxysterol-generating enzyme Cyp46a1 is overexpressed during the angiogenic switch in rat insulin promoter 1–T-antigen 2 (RIP1-Tag2) pNET formation. Moreover, we report that Cyp46a1 overexpression requires hypoxia inducible factor-1a (HIF-1α). Importantly, we show that pharmacologic blockade and genetic inactivation of 24S-HC delays angiogenic switch and therefore tumor formation in RIP1-Tag2. Overexpression of Cyp46a1 transcripts in some human pNET samples suggests that targeting this axis in patients affected by pancreatic neuroendocrine tumors may be an effective therapeutic strategy.


Related Papers

No related papers found

Powered by citation graph analysis